patient assessment News
-
iFIT’s immediate fitting technology allows for initial assessments and easy follow up during Telehealth visits
Your patients shouldn't have to wait for months to get the help they need. Amputees can suffer greatly with less movement, leading to more muscle atrophy, greater deconditioning, and reduced joint range of motion. iFIT can help with assessing your patients’ needs via Telehealth. Trouble shoot the situation together Simple solutions for modification Make cable adjustments easily ...
-
Osteoporosis in Older Patients Easy Assessment Easy Assessment of Osteoporosis in Older Patients
According to the National Osteoporosis Foundation (NOF), about 54 million Americans suffer from osteoporosis, presenting low bone mass, and suffering from brittle-bone related injuries, such as fractures, and broken bones. In fact, the disease is responsible for “two million broken bones and $19 billion in related costs every year”, while by the year 2025, “experts predict that ...
By BeamMed Inc.
-
Showcase
Are the patients able to perform the home spirometry with AioCare?
The Journal of Asthma published the results of a study that assessed asthma patients and their ability to perform high-quality daily spirometry with the AioCare system. The study has shown that home spirometry is safe without supervision and feasible for asthma patients. Abstract: Background: Self-management is an appealing strategy for the prevention of asthma exacerbations. This study aimed ...
By AioCare
-
Hemostemix Partners with My Next Health, Obtains USD $150,000 Subscription at CAD $0.25 Per Unit, and Incorporates Functional Genomics
Hemostemix Inc. (“Hemostemix” or the “Company”) (TSXV:HEM; OTCQB:HMTXF; FSE:2VFO) is pleased to announce it has signed a Global Master Services Agreement with My Next Health (“MNH”), and has, subject to TSXV approval, obtained a subscription from My Next Health in the amount of USD $150,000 at CAD $0.25 per Unit. My Next Health Inc. (“MNH”) is the ...
-
Caladrius Biosciences Announces IDMC Recommendation to Advance CLBS201 Trial for the Treatment of Diabetic Kidney Disease
BASKING RIDGE, N.J., May 19, 2022 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the development of innovative therapies designed to treat or reverse disease, today announced that the Independent Data Monitoring Committee (“IDMC”) overseeing the Phase 1b, ...
-
Cardiac telerehabilitation system implemented in Przemysl, southeast of Poland
In times of pandemic, cardiac rehabilitation centres search for solutions which allow them to continue remote rehabilitation, while making it possible to maintain constant contact with the patient. This solution must provide possibility to assess the patient's condition before training, set training parameters adjusted to individual needs and must ensure easy access to records from rehabilitation ...
By Pro-PLUS SA
-
AIDOC and IMBIO partner to provide an industry first ai solution to prioritize suspected pulmonary embolism and automatically calculate RV/LV ratio
Aidoc, the leading provider of enterprise AI solutions, and Imbio, a leading provider of medical image analysis for pulmonary and cardiothoracic diseases, announced today a partnership intended to provide the world’s first end-to-end AI solution for pulmonary embolism (PE), with the goal of ultimately improving efficiency and quality of pulmonary embolism detection and treatment. ...
By Aidoc
-
Kardium® announces successful results from the GLOBAL-AF study
VANCOUVER, British Columbia — Kardium Inc. today announced that the Globe® Mapping and Ablation System has successfully demonstrated safety and efficacy in the GLOBAL-AF study. The results of the study were published in the Journal of Cardiovascular Electrophysiology. The study demonstrated a 76% percent freedom from atrial fibrillation at 12 months after a single treatment with the ...
By Kardium Inc.
-
CathWorks FFRangio System outcomes study to be presented at ACC 2022
CathWorks announced today that the results of its most recent outcomes study on the CathWorks FFRangio™ system will be presented by Dr. Guy Witberg from Rabin Medical Center, Petah Tikva, Israel on Sunday, April 3 at the annual American College of Cardiology (ACC) conference in Washington, DC. Dr. Witberg and his co-investigators in Israel and Japan examined the 1-year clinical outcomes of ...
By CathWorks
-
Bodyport raises $11.2 million in Series A funding to launch virtual cardiac clinic
Bodyport, the digital health company focused on the detection and management of heart disease, today announced the close of an $11.2 million Series A investment round. Boehringer Ingelheim Venture Fund (BIVF) led the round and was joined by existing investors Playground Global, Initialized Capital, Y Combinator and Hardware Club, as well as new investors Kapor Capital and Regah Ventures. The ...
-
Galera Announces Topline Results from Phase 2a AESOP Trial of Avasopasem for Chemoradiotherapy-Induced Esophagitis
No Grade 4 or 5 esophagitis in patients treated with avasopasem Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today announced topline results from the six-week, Phase 2a, open-label, single-arm AESOP trial of ...
-
ZAP Surgical Brain Tumor Treatments Commence at PLA General Hospital 301 in Beijing, China
SAN CARLOS, Calif., Jan. 14, 2020 /PRNewswire/ -- ZAP Surgical Systems, Inc. today announced that its ZAP-X® Gyroscopic Radiosurgery™ platform began clinical stereotactic radiosurgery (SRS) treatments at PLA General Hospital 301 (PLAGH 301) in Beijing, China. PLAGH 301 is the largest hospital in China with more than 20,000 outpatient treatments per day. For select indications ...
-
Genenta Progresses to Higher Dosing Cohort in Temferon™ Phase 1/2a Clinical Trial in Glioblastoma Multiforme
Genenta Science (NASDAQ: GNTA), a clinical-stage biotechnology company pioneering the development of hematopoietic stem progenitor cell immuno-gene therapy for cancer, announces that its ongoing trial of Temferon™ in glioblastoma multiforme patients who have an unmethylated MGMT gene promoter (uMGMT-GBM) has escalated to the next planned dose. With no drug-limiting toxicities observed at ...
-
JenaValve Receives IDE Approval to Initiate The ALIGN-AR Pivotal PMA Trial
JenaValve Technology, Inc., developer, and manufacturer of differentiated transcatheter aortic valve replacement (TAVR) systems, today announced FDA approval for the company to initiate its Investigational Device Exemption (IDE) PMA clinical trial for the Trilogy™ Heart Valve System for severe symptomatic, high-surgical risk aortic regurgitation. Aortic regurgitation (AR) is a condition ...
-
I heard elderly people with diabetes are more likely to break bones
Walking in a crowd, six out of ten elderly people are at risk for diabetes. Nowadays, diabetes has become the most common disease among the elderly. Studies have shown that women with diabetes have an increased risk of fractures. In men, however, the relationship between diabetes and fracture risk is unclear. For a time, the grandfathers in the diabetes specialized hospital, start road, were ...
-
Analysis of the cryolipolysis slimming machine advantages and disadvantages
Cryolipolysis is a medical aesthetic technique that uses freezing to break down excess fat in the body to achieve a slimming effect. This technique has a great popularity and many people feel confident and beautiful because of the success of this technique to lose weight. As we all know, the medical aesthetic industry has always been a hot industry and cryolipolysis beauty machine as a technique ...
-
Michelson Diagnostics teams up with AI Specialists Manchester Imaging to develop Machine Learning Algorithms for VivoSight OCT Skin Imaging System
Michelson Diagnostics Ltd, manufacturer of the world-leading VivoSight OCT skin imaging and measurement system, has teamed up with AI specialists Manchester Imaging Ltd, to aid dermatologists in the fight against skin cancer and other skin diseases. Michelson’s VivoSight Dx OCT scanner is used by trained dermatologists in their assessment of suspicious skin lesions, and is already in ...
-
Digitsole Pro® is FDA Registered Class II - Innovative AI-Based Solution for Clinical Assessment of Mobility Disorders
Digitsole, a leader in the digital health space bringing together digital mobility biomarkers and biomechanical data with clinical expertise, has received Class II medical device registration with the U.S. Food and Drug Administration (FDA) for its Digitsole Pro® smart insoles. Digitsole Pro®, recently launched in the United States, is a solution, developed with, and for ...
By Digitsole
-
Calviri Awarded NCI Grant for the Development of a New Blood Test That May Predict Responders to Checkpoint Inhibitor Therapies
Calviri, Inc., a start-up focused on ending deaths from cancer through unconventional approaches to diagnostics and vaccines, was recently awarded a $300,000 Phase I grant through the Small Business Innovation Research Program (SBIR) at the National Cancer Institute (NCI). This one-year grant will support the development of a new test for establishing whether a cancer patient’s tumor has ...
By Calviri
-
BrainScope Launches Next-Gen Medical Device: First and only FDA-cleared system for true point-of-care assessment of both concussion and brain bleeds now includes Concussion Index
BrainScope today announced the availability of its third groundbreaking FDA-cleared algorithm on the BrainScope device. The Concussion Index is the first physiological marker of concussive injury that aids clinicians in the objective assessment of patients at baseline, point of injury, and through recovery. The Concussion Index adds to the suite of FDA cleared algorithms already available on the ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you